Population-Level Risk Factors for Kidney Outcomes in IgA Nephropathy: The CURE-CKD Registry.
Publication Title
Kidney Med
Document Type
Article
Publication Date
4-1-2025
Keywords
washington; spokane; pmrc
Abstract
RATIONALE & OBJECTIVE: Although IgA nephropathy (IgAN) therapies are advancing quickly, therapeutic interventions are hampered by a lack of kidney disease identification and risk assessment. The study aim was to use population-level data from health systems to identify IgAN and assess risks.
STUDY DESIGN: A longitudinal and real-world cohort study.
SETTING & PARTICIPANTS: Electronic health record data for patients ≥18 years old with IgAN at Providence and University of California Los Angeles health systems during 2016-2022.
PREDICTORS: Health insurance and care utilization along with age, gender, race, ethnicity, estimated glomerular filtration rate (eGFR), urine albumin/creatinine ratio (UACR) or urine protein/creatinine ratio (UPCR), diabetes, hypertension, and medications.
OUTCOMES: Time to first major adverse kidney event (MAKE): ≥40% eGFR decline; eGFR < 15 mL/min/1.73 m2; administrative codes for kidney failure, dialysis, or transplant; and death.
ANALYTICAL APPROACH: Kaplan-Meier survival curves and Cox proportional hazards models.
RESULTS: Patients with IgAN (n = 2,571) were 50% (n = 1,277) women and 58 ± 18 (mean ± SD) years old. At baseline, eGFR was 78 ± 27 mL/min/1.73 m
LIMITATIONS: Missingness, miscoding, and retrospective data.
CONCLUSIONS: Substantial loss of kidney function, kidney failure, and death were common events over a short period of time in patients with IgAN. Within health system populations, noncommercial health insurance and greater care utilization augmented risk prediction and could help to identify those who may benefit from closer monitoring and implementation of therapeutic interventions.
Area of Special Interest
Kidney & Diabetes
Specialty/Research Institute
Endocrinology
Specialty/Research Institute
Nephrology
DOI
10.1016/j.xkme.2025.100981